The UK Prospective Diabetes Study (UKPDS) has revealed that metformin reduced the risk of all-cause mortality and stroke clinically; however, these benefits were independent of its anti-hyperglycemic effects, since metformin reduced glycated hemoglobin (HbA1c) to the same extent as sulphonylurea and insulin [5]. The gene discussed is INS; the disease is diabetes mellitus.